drugset / Trial / NCT00768755
Evaluation Of The Efficacy Of The Combination Of Axitinib With Pemetrexed And Cisplatin In The Treatment Of Non-Squamous Non-Small Cell Lung Cancer
RandomizedSingle-groupOpen-labelTreatment
Summary
AG-013736 (axitinib) in combination with cisplatin and pemetrexed will be evaluated as first-line treatment of patients with locally advanced, recurrent, or metastatic non-squamous, non small cell lung cancer (NSCLC).
Timeline
- Start
- 2009-01
- Primary completion
- 2011-03
- Completion
- 2012-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Axitinib | Small molecule | 10 mg | Oral |
| Comparator | Cisplatin | Other / unclassified | 75 mg/m2 | — |
| Comparator | Pemetrexed | Small molecule | 500 mg/m2 | — |